A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
|Articles|October 1, 1998
Oncology NEWS International
- Oncology NEWS International Vol 7 No 10
- Volume 7
- Issue 10
M.D. Anderson Center Will Consolidate Faculty Offices in New Building in 2000
HOUSTON--A new faculty center will allow M.D. Anderson Cancer Center to consolidate faculty offices currently located in several buildings on its main campus. The new facility, approved by the University of Texas System Board of Regents last August, will be constructed on the south side of Holcombe Boulevard, adjacent to the Jesse H. Jones Rotary House International patient/family hotel and directly across the street from M.D. Anderson’s main clinic and hospital complex (figure).
Advertisement
HOUSTON--A new faculty center will allow M.D. Anderson Cancer Center to consolidate faculty offices currently located in several buildings on its main campus. The new facility, approved by the University of Texas System Board of Regents last August, will be constructed on the south side of Holcombe Boulevard, adjacent to the Jesse H. Jones Rotary House International patient/family hotel and directly across the street from M.D. Andersons main clinic and hospital complex (figure).
The $45.4 million faculty center will include 13 floors for physicians offices and support functions as well as a food court, copy center, mail services, and a sky bridge that connects the building to the Rotary House. An existing bridge links Rotary House to M.D. Andersons clinic and hospital buildings.
Construction is scheduled to begin in the spring of 1999, with completion expected by the fall of 2000.
Articles in this issue
almost 28 years ago
Panel Recommends Photofrin for Use in Late-Stage Lung Canceralmost 28 years ago
California Intervention Raises Consumption of Fruits and Vegetablesalmost 28 years ago
ODAC Panel Okays Nolvadex to Reduce Breast Cancer Riskalmost 28 years ago
Evolving Role for Preoperative Chemo in Breast Canceralmost 28 years ago
NCI Sets Sail on a New Tack In the Stormy Seas of CAMalmost 28 years ago
Opioid Antagonists Can Control Opioid-Induced Constipationalmost 28 years ago
NCI Seeks New Technologiesalmost 28 years ago
NIAID Collaborates With VaxGen, Inc. on Trials of AIDSVAXalmost 28 years ago
Clinicians Often Fail To Provide Adequate Genetic CounselingAdvertisement
Related to this article
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5